Strug­gling On­colyt­ics Biotech signs $86.6M Asia deal with Chi­na's Ad­lai Nortye

Cal­gary, Cana­da-based On­colyt­ics Biotech has struck an $86.6 mil­lion li­cens­ing deal with Chi­na’s Ad­lai Nortye for its IV im­muno-on­colyt­ic virus. Pay­ing $5.3 mil­lion up­front with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER